7-hydroxystaurosporine has been researched along with Disease Models, Animal in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cabezas-Herrera, J; Fernández-Pérez, MP; Montenegro, MF; Piñero-Madrona, A; Rodríguez-López, JN; Sáez-Ayala, M; Sánchez-del-Campo, L | 1 |
| Jung, IL; Kim, SY; Kwon, YW; Park, SG; Sung, JH | 1 |
| Aprelikova, O; Bennett, CN; Caplen, NJ; Chu, IM; Green, JE; Hollingshead, MG; Luger, D; Michalowski, AM; Mittereder, LR; Piwinica-Worms, H; Shou, J; Tomlinson, CC | 1 |
3 other study(ies) available for 7-hydroxystaurosporine and Disease Models, Animal
| Article | Year |
|---|---|
Suppression of antifolate resistance by targeting the myosin Va trafficking pathway in melanoma.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Cell Line, Tumor; Disease Models, Animal; Drug Resistance, Neoplasm; E2F1 Transcription Factor; Enzyme Activation; Female; Gene Silencing; Humans; Melanoma; Methotrexate; Methylation; Mice; Myosin Heavy Chains; Myosin Type V; Phosphoprotein Phosphatases; Phosphorylation; Protein Phosphatase 2C; Protein Transport; Proto-Oncogene Proteins c-akt; Signal Transduction; Staurosporine; Xenograft Model Antitumor Assays | 2013 |
Tauroursodeoxycholate (TUDCA) inhibits neointimal hyperplasia by suppression of ERK via PKCα-mediated MKP-1 induction.
Topics: Animals; Apoptosis; Biological Transport; Carotid Artery Injuries; Cell Movement; Cell Proliferation; Cell Survival; Cells, Cultured; Cytoprotection; Disease Models, Animal; Dose-Response Relationship, Drug; Dual Specificity Phosphatase 1; Enzyme Activation; Extracellular Signal-Regulated MAP Kinases; Humans; Hyperplasia; Liver-Specific Organic Anion Transporter 1; Matrix Metalloproteinase 9; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; Phosphorylation; Protein Kinase C-alpha; Protein Kinase Inhibitors; Rats; Rats, Sprague-Dawley; RNA Interference; Staurosporine; Taurochenodeoxycholic Acid; Time Factors; Transfection; Tunica Intima; Up-Regulation | 2011 |
Cross-species genomic and functional analyses identify a combination therapy using a CHK1 inhibitor and a ribonucleotide reductase inhibitor to treat triple-negative breast cancer.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Checkpoint Kinase 1; Cluster Analysis; Deoxycytidine; Disease Models, Animal; DNA Damage; Dose-Response Relationship, Drug; Drug Synergism; Female; Gemcitabine; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Inhibitory Concentration 50; Mice; Protein Kinase Inhibitors; Protein Kinases; Retinoblastoma Protein; Ribonucleoside Diphosphate Reductase; Ribonucleotide Reductases; RNA Interference; RNA, Small Interfering; Staurosporine; Triple Negative Breast Neoplasms; Tumor Burden; Tumor Suppressor Protein p53; Tumor Suppressor Proteins; Xenograft Model Antitumor Assays | 2012 |